Comparison of human isophane insulin (Human InsulatardTM) with crystalline insulin zinc suspension (Human UltratardTM) as night-time longer-acting insulins in a multiple injection regimen
✍ Scribed by Mansell, P I ;Havard, F ;O'Hare, J P
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 501 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1357-8170
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In a randomised cross‐over study we compared human isophane insulin (Human Insulatard^TM^) with human crystalline insulin zinc suspension (Human Ultratard^TM^) as longer‐acting, night‐time insulins given thrice daily soluble insulin in the management of diabetes. We studied 20 insulin‐dependent patients aged 20–47 years. At the end of each 12‐week study period, total daily insulin dose was 56.9 ± 3.9U with Human Insulatard^TM^ and 59.4 ± 4.4U with Human Ultratard^TM^ (no significant difference). The amount of longer‐acting insulin used was lower with Human Insulatard^TM^ than with Human Ultratard^TM^ (23.3 ± 2.5 vs 29.0 ± 3.2U per day, p<0.001), despite which the early morning (fasting) blood glucose concentration was lower using Human Insulatard^TM^ (7.4 ± 0.6 vs 10.0 ± 1.0mmol per litre, p<0.02). Serum fructosamine, glycosylated haemoglobin and mean daily blood glucose concentrations were similar with either insulin. Patients reported a total of 85 (range 0.25, median 2) hypoglycaemic episodes using Human Insulatard^TM^ compared with 161 (0.33, 3) when using Human Ultratard^TM^ (0.05 TM compared with five choosing Human Ultratard^TM^ (p<0.05). In many patients, human isophane insulin appears to be more satisfactory than human crystalline insulin zine suspension as a longer acting insulin in a multiple injection regimen.